TravivoTreatment for Depression
Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder
HOUSTON, LONDON and RESEARCH TRIANGLE PARK, N.C., November 02, 2007 /PRNewswire/ -- Fabre-Kramer Pharmaceuticals Inc. (FKP) and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has issued a not approvable letter for the new drug application for gepirone extended- release (ER) tablets, submitted for the treatment of adults with major depressive disorder.
The FDA had previously reviewed Phase I through III clinical data involving gepirone ER. In June 2004, the FDA requested an additional positive short-term trial in order to consider gepirone ER for approval as a new antidepressant treatment. Subsequently, FKP successfully conducted a trial in patients with major depressive disorder to respond to the FDA request for an additional positive pivotal study.
Those results were submitted to the FDA in May 2007. The not approvable letter issued today is based on the FDA review of those additional results along with other newly submitted and previously submitted data.
Fabre-Kramer and GlaxoSmithKline entered an agreement in February of this year for collaboration on the worldwide development and commercialization of gepirone extended-release tablets. Fabre-Kramer and GSK are evaluating the response from the FDA to determine appropriate next steps.
About Fabre-Kramer Pharmaceuticals
Fabre-Kramer Pharmaceuticals, headquartered in Houston, Texas, is engaged in acquiring, developing and commercializing psychotropic drugs that have significant market potential. In addition to gepirone ER, Fabre-Kramer has 10 other compounds in various stages of development for indications including depression, anxiety, schizophrenia, Parkinson's disease and insomnia. For more information, visit FKP's website at www.fabrekramer.com
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit GlaxoSmithKline on the World Wide Web at www.gsk.com.
CONTACT: US Inquiries: GSK US Media Inquiries, Marc Meachem or Mary AnneRhyne, +1-919-483 2839; GSK US Analyst/Investor inquiries: Frank Murdolo,+1-215-751-7002 or Tom Curry, +1-215-751 5419; Fabre-Kramer Inquiries:Edward Koehler, +1-713-975-6900; UK Inquiries: GSK UK Media Inquiries,Alice Hunt and Joss Mathieson, (020) 8047 5502; GSK UK Analyst/Investorinquiries: David Mawdsley, (020) 8047 5564 or Sally Ferguson, (020) 80475543
Company News On-Call: http://www.prnewswire.com/comp/801350.html /
Ticker Symbol: (NYSE:GSK)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: November 2007
- FDA Rules Favorably On Efficacy Of Travivo (Gepirone ER) For Treatment Of Major Depressive Disorder - March 17, 2016
- Fabre-Kramer Looks Forward to FDA's Decision on Gepirone ER for the Treatment of Major Depressive Disorder - December 2, 2015
- Fabre-Kramer Refiles Gepirone ER with the FDA for the Treatment of Major Depressive Disorder - May 8, 2007